AcelRx Pharmaceuticals Inc
F:R5X
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
C
|
CRH PLC
NYSE:CRH
|
IE |
AcelRx Pharmaceuticals Inc
Total Assets
AcelRx Pharmaceuticals Inc
Total Assets Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Total Assets | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
AcelRx Pharmaceuticals Inc
F:R5X
|
Total Assets
$23.3m
|
CAGR 3-Years
-29%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-12%
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Total Assets
$199.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
3%
|
CAGR 10-Years
4%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Total Assets
$90B
|
CAGR 3-Years
-2%
|
CAGR 5-Years
-5%
|
CAGR 10-Years
11%
|
|
|
Pfizer Inc
NYSE:PFE
|
Total Assets
$208.2B
|
CAGR 3-Years
2%
|
CAGR 5-Years
6%
|
CAGR 10-Years
2%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Total Assets
$136.9B
|
CAGR 3-Years
8%
|
CAGR 5-Years
8%
|
CAGR 10-Years
3%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Total Assets
$112.5B
|
CAGR 3-Years
31%
|
CAGR 5-Years
19%
|
CAGR 10-Years
12%
|
|
AcelRx Pharmaceuticals Inc
Glance View
AcelRx Pharmaceuticals, Inc. engages in the development and commercialization of therapies use in medically supervised settings. The company is headquartered in Hayward, California and currently employs 43 full-time employees. The company went IPO on 2011-02-11. The firm is focused on the development and commercialization of therapies for use in medically supervised settings. Its portfolio of products and product candidates consists of sufentanil sublingual products and product candidates, pre-filled syringe product candidates and nafamostat mesylate product candidates. Its sufentanil sublingual products include DSUVIA, DZUVEO and Zalviso, which are focused on the treatment of moderate-to-severe acute pain in a medically supervised setting. Its pre-filled syringe product candidates include Ephedrine and Phenylephrine. Its nafamostat mesylate product candidates include Niyad, which is a regional anticoagulant for injection into the extracorporeal circuit, and LTX-608, which is a nafamostat formulation for antiviral treatment of COVID, acute respiratory distress syndrome (ARDS), disseminated intravascular coagulation (DIC), and acute pancreatitis.
See Also
What is AcelRx Pharmaceuticals Inc's Total Assets?
Total Assets
23.3m
USD
Based on the financial report for Sep 30, 2023, AcelRx Pharmaceuticals Inc's Total Assets amounts to 23.3m USD.
What is AcelRx Pharmaceuticals Inc's Total Assets growth rate?
Total Assets CAGR 10Y
-12%
Over the last year, the Total Assets growth was -52%. The average annual Total Assets growth rates for AcelRx Pharmaceuticals Inc have been -29% over the past three years , -21% over the past five years , and -12% over the past ten years .
